Seres Therapeutics Names Eric D. Shaff to Additional Role of COO
7 February 2018 - - Cambridge, Massachusetts-based microbiome therapeutics platform company Seres Therapeutics, Inc. has appointed Eric D. Shaff to the additional role of chief operating officer, the company said.
Shaff has been executive vice president and chief financial officer since joining the company in November 2014, and he will continue to retain both positions.
He also serves on the board of directors for Sigilon Therapeutics and has extensive experience in the biotechnology field, having worked at Momenta Pharmaceuticals and Genzyme Corp., where he was vice president of finance for the Personalized Genetic Health division.
Shaff received his B.A. from the University of Pennsylvania and his MBA from Cornell University.
The company's lead programme, SER-109, is in Phase 3 development for multiply recurrent C. difficile infection. Its clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate UC.
The company's is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection.
Seres Therapeutics is developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.